Starpharma Holdings's EBIT per Share for the
six
months ended in Dec. 2025 was A$0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.01.
During the past 3 years, the average EBIT per Share Growth Rate was 13.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 12.00% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 6.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Starpharma Holdings's EBIT per Share or its related term are showing as below:
ASX:SPL'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -31.8 Med: 1.55 Max: 22.6
Current: 13
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Starpharma Holdings was 22.60% per year. The lowest was -31.80% per year. And the median was 1.55% per year.
ASX:SPL's 3-Year EBIT Growth Rate is ranked worse than 52.84% of 1181
companies
in the Biotechnology industry
Industry Median: 15.5
vs ASX:SPL: 13.00
Starpharma Holdings (ASX:SPL) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Starpharma Holdings EBIT per Share Related Terms
Starpharma Holdings EBIT per Share Historical Data
* Premium members only.
The historical data trend for Starpharma Holdings's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Starpharma Holdings (ASX:SPL) has a EBIT per Share of A$-0.01 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Starpharma Holdings and its competitors. According to the industry distribution chart, Starpharma Holdings ranks #624 out of 1181 companies in the Biotechnology industry, placing it in the top 52.8%.
Is Starpharma Holdings' EBIT per Share too high?
Starpharma Holdings' current EBIT per Share is A$-0.01. Based on the distribution chart, Starpharma Holdings ranks #624 out of 1181 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Starpharma Holdings has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starpharma Holdings' EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Starpharma Holdings ranks #624 out of 1181 companies for EBIT per Share. This places Starpharma Holdings in the lower half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,181 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Starpharma Holdings and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Starpharma Holdings's current EBIT per Share is A$-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starpharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Starpharma Holdings (ASX:SPL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.43, compared to a current price of A$0.70 — trading 62.8% above its estimated fair value. The current EBIT per Share is A$-0.01. Starpharma Holdings' overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Starpharma Holdings (ASX:SPL), the current EBIT per Share is A$-0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Starpharma Holdings (ASX:SPL) Overvalued in 2026?
Based on GuruFocus' analysis, Starpharma Holdings stock appears to be overvalued.
The current stock price of A$0.70 is trading 62.8% above its estimated GF Value™ of A$0.43.
GuruFocus considers Starpharma Holdings to be Significantly Overvalued.
Key valuation signals for ASX:SPL:
EBIT per Share: A$-0.01
GF Value™: A$0.43 vs. price of A$0.70 (62.8% above fair value)
No single metric tells the full story. See the ASX:SPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.
53GF Score
Get the complete analysis for ASX:SPL
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:SPL has been successfully added to your 
